HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Badry Bursulaya Selected Research

nazartinib

3/2016EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.
1/2016Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Badry Bursulaya Research Topics

Disease

6Neoplasms (Cancer)
12/2021 - 08/2003
2Adenocarcinoma of Lung
12/2021 - 04/2020
2Leishmaniasis
10/2020 - 01/2016
2Chagas Disease (American Trypanosomiasis)
10/2020 - 01/2016
2Non-alcoholic Fatty Liver Disease
01/2020 - 12/2017
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2016 - 02/2016
2Infections
01/2016 - 12/2013
2Lung Neoplasms (Lung Cancer)
01/2016 - 01/2016
2Malaria
11/2011 - 11/2010
1African Trypanosomiasis (Nagana)
10/2020
1Inflammation (Inflammations)
01/2020
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2020
1Fibrosis (Cirrhosis)
01/2020
1Hyperglycemia
01/2020
1Cholestasis
12/2017
1Liver Diseases (Liver Disease)
12/2017
1Neuroblastoma
02/2016
1Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
02/2016
1Neglected Diseases
01/2016
1Autoimmune Diseases (Autoimmune Disease)
04/2014
1Metabolic Syndrome (Dysmetabolic Syndrome X)
04/2014
1Tuberculosis (Tuberculoses)
11/2012
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
10/2010

Drug/Important Bio-Agent (IBA)

6Phosphotransferases (Kinase)IBA
12/2021 - 10/2010
2pyrimidineIBA
12/2021 - 04/2020
2GNF6702IBA
10/2020 - 01/2016
2Proteasome Endopeptidase Complex (Proteasome)IBA
10/2020 - 01/2016
2LipidsIBA
01/2020 - 12/2013
2Bile Acids and Salts (Bile Acids)IBA
12/2017 - 04/2014
2ErbB Receptors (EGF Receptor)IBA
03/2016 - 01/2016
2nazartinibIBA
03/2016 - 01/2016
1Proteasome InhibitorsIBA
10/2020
1LXE408IBA
10/2020
16-azaindoleIBA
01/2020
1Insulin (Novolin)FDA Link
01/2020
1tropifexorIBA
12/2017
1Anaplastic Lymphoma KinaseIBA
02/2016
1LigandsIBA
02/2016
1Cetuximab (Erbitux)FDA Link
01/2016
1EAI045IBA
01/2016
1Adenosine Triphosphate (ATP)IBA
01/2016
1Tyrosine Kinase InhibitorsIBA
01/2016
1AfatinibIBA
01/2016
1Gefitinib (Iressa)FDA Link
01/2016
1Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2016
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
04/2014
1GTP-Binding Proteins (G-Protein)IBA
04/2014
1Antimalarials (Antimalarial Agents)IBA
12/2013
1NitroimidazolesIBA
11/2012
1DecoquinateIBA
11/2011
1Anti-Bacterial Agents (Antibiotics)IBA
11/2010
1Clindamycin (Cleocin)FDA LinkGeneric
11/2010
1Quinine (Quinson)FDA Link
11/2010
1Imatinib Mesylate (Gleevec)FDA Link
10/2010
1Inhibitor of Apoptosis ProteinsIBA
08/2003

Therapy/Procedure

6Therapeutics
12/2021 - 11/2010